Navigation Links
Zogenix Initiates Pivotal Phase 3 Clinical Trial for Novel Formulation of Oral Controlled-Release Hydrocodone
Date:3/17/2010

SAN DIEGO, March 17 /PRNewswire/ -- Zogenix, Inc. ("Zogenix"), a privately held pharmaceutical company, announced that it has initiated a pivotal Phase 3 clinical trial with ZX002, a novel, oral, controlled-release formulation of hydrocodone without acetaminophen.  ZX002 is being developed for the treatment of moderate to severe pain in individuals who require around-the-clock opioid therapy for the control of pain.  Hydrocodone is the most widely prescribed drug in the United States, but there are currently no products available with hydrocodone only, or with controlled-release formulations.  ZX002, which incorporates Elan's proprietary SODAS® technology, offers a unique controlled-release profile which utilizes both immediate release and extended release properties designed to enable twice daily dosing.

"We are pleased to be initiating this pivotal Phase 3 trial of ZX002 as the first single-entity, controlled-release hydrocodone formulation," said Cynthia Robinson, Ph.D., chief development officer of Zogenix.  "We believe this hydrocodone therapy could offer significant benefits to both the patient and the practicing physician by allowing for less frequent dosing with a customized controlled-release profile and the ability to titrate to higher hydrocodone doses than currently recommended for hydrocodone products burdened by combination formulations. Further, we believe ZX002 may offer patients an option for the treatment of their chronic pain that potentially avoids some of the serious side effects that can accompany chronic use of combination opioids that contain acetaminophen, or other n
'/>"/>

SOURCE Zogenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
2. ISIS Initiates Phase 1 Clinical Trial of ISIS-SOD1Rx in Patients With ALS
3. Kinex Pharmaceuticals Initiates a Phase 2 Clinical Trial of KX2-391 in Patients with Prostate Cancer
4. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
5. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
6. Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui
7. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
8. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
9. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
10. Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression
11. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... and DUBLIN , Jan. 23, 2015 ... with KRS Global Biotechnology, Inc. for the compounding, packaging and ... for shipment in the United States . ... Outsourcing Facility capable of compounding naltrexone tablets in various strengths ...
(Date:1/23/2015)... Jan. 23, 2015  iMD Companies, Inc. (ICBU) has repositioned itself ... share and grab a foothold in the hydroponic, hemp and ... and a presence in the sector, and recently partnering with ... of hemp and medical marijuana, iMD is committing to bring ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... Directors has approved a share repurchase program. The open-ended ... million of Mallinckrodt plc ordinary shares. ... remain top priorities as we continue to pursue a ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... N.C. , July 23 Sales executives agree that ... process. Yet only 6 percent of district sales managers currently understand ... , , , ... knowledge of health outcomes, evidence based medicine and reimbursement," states an ...
... July 23 The North Shore-LIJ Health System Department of ... oropharynx (back of the mouth) to participate in a Phase I clinical ... Subjects must be ... must be unassociated with the human papilloma virus (HPV-negative), or, if it ...
Cached Medicine Technology:Health Outcomes Data Essential to Biopharmaceutical Sales Process 2Health Outcomes Data Essential to Biopharmaceutical Sales Process 3Study Seeks Volunteers to Measure Safety of Treatment 'Boost' for Patients with Oropharyngeal Cancer 2
(Date:1/22/2015)... 23, 2015 LunaDress, with its top dressmaking ... industry. Now, the business is showing its latest designs of ... , According to the company’s CEO, all the fresh new ... with big discounts, up to 80% off. All the clothes ...
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort located in ... number one best large hotel for families in the United ... annual Travelers’ Choice Awards. , TripAdvisor represents the world’s ... to millions of unbiased and honest traveler reviews. The best ...
(Date:1/22/2015)... 2015 Padre Murphy's and Owner Tom Boyle ... Pro Player Health Alliance (PPHA). The PPHA's passion for ... everyone, including NFL greats, treated for obstructive sleep apnea (OSA) ... supporting the cause in the valley. The most recent plans ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The Incredible Bulk ... Ben Pakulski to increase lean muscle by up to 30lbs ... caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative ... it is a step-by-step, scientific diet formula that allows the ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) ... to “Live Fearless.” , The “Faces of Fearless” ... about how they or someone they know has faced a ... the moment. By telling these types of stories through livefearlessmn.com, ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2
... Sept. 17 Adlyfe, a private company,developing novel ... announced today that it has appointed Roxanne Duan, ... be responsible for overseeing,the Adlyfe,s Research efforts and ... Duan comes to Adlyfe with nearly two decades ...
... Symmetry Medical Inc.,(NYSE: SMA ), an ... industry and other medical markets, announced today the ... http://www.symmetrymedical.com, which contains improved,user- friendly features. ... provides easy to,find product information and a streamlined ...
... affect asthma type, study concludes, , , MONDAY, Sept. ... affect the type of asthma you develop, new ... youngsters in affluent, developed countries had more allergy-triggered ... developed countries. , "The link between atopic ...
... available, researchers must recruit hundreds or thousands of patients ... patients is often difficult. Many potential candidates are unaware ... logistical hurdles. As a result, patients miss out on ... therapies take longer to reach the public., In a ...
... Sept. 17 CryoCor, Inc. (Nasdaq:,CRYO), a medical device ... that Edward F. Brennan, President and Chief,Executive Officer, and ... at the Maxim Group First Annual Growth Conference in,New ... a.m. ET at The Grand,Hyatt Hotel. A live ...
... largest public health challenges, including AIDS, should be part of Presidential ... ... plans, WASHINGTON, Sept. 17 More than 100,organizations ... to ending the AIDS epidemic in America. They have requested that,every ...
Cached Medicine News:Health News:Adlyfe Appoints Roxanne Duan as Vice President of Research 2Health News:Adlyfe Appoints Roxanne Duan as Vice President of Research 3Health News:Symmetry Medical Launches New Global Web site 2Health News:Symmetry Medical Launches New Global Web site 3Health News:Allergy-Induced Asthma More Common in Affluent Countries 2Health News:Allergy-Induced Asthma More Common in Affluent Countries 3Health News:IMPACT initiative looks to improve patient participation in clinical trials 2Health News:CryoCor to Present at Maxim Group First Annual Growth Conference in New York 2Health News:More Than 100 Organizations Call for a National AIDS Strategy to End the Epidemic in the United States 2Health News:More Than 100 Organizations Call for a National AIDS Strategy to End the Epidemic in the United States 3
Two point fixation, tips separated by 13 mm. Each tip has 0.12 mm, 1 x 2 teeth. Wide serrated handle with thumb catch lock and dull finish....
... A simple, effective method for determining color ... reliable data which can be applied to ... The set consists of four trays containing ... caps that have incremental hue variation on ...
... Farnsworth 100 Hue Test including MS-Excel scoring template ... Farnsworth 100 Hue Test comes boxed in clear ... the potential for test disruption by holding ... test from Richmond Products includes 93 color discs, ...
... modification of the Farnsworth-Munsell 100 Hue Test. It ... the in-depth study of a color vision defect. ... ease or difficulty in distinguishing color differences in ... 15 color reference caps with Munsell notations, plus ...
Medicine Products: